Sandoz Limited has advised of an error regarding the sugar content of several batches of co-amoxiclav powder for oral suspension

The affected lines are

• Co-amoxiclav 125/31.25mg/5ml powder for oral suspension
• Co-amoxiclav 125/31.25mg/5ml powder for oral suspension (Almus livery)
• Co-amoxiclav 250/62.5mg/5ml powder for oral suspension
• Co-amoxiclav 250/62.5mg/5ml powder for oral suspension (Almus livery)

Sandoz limited has informed the MHRA that affected products are not sugar free despite the carton stating ‘sugar free’.

All batches supplied since December 2008 have contained a very small quantity of sugar originating from the flavouring. The contained sugars are dextrose and maltodextrin, which are both composed of glucose. The total amount of sugar at the maximum daily doses equates to 204.3 mg in children, 127.8 mg in adults.

Affected batches are not being recalled. Healthcare professionals are advised to inform patients about the error when dispensing subsequent batches or in discussion with patients who may have concerns related to sugar intake or glucose control.

For more information, medical information queries, please contact: [email protected], Telephone: +44 1276 698 101

For stock control queries, please contact: [email protected], Telephone: +44 1276 698607